About
Zealand Pharma A/S is a biopharmaceutical company specializing in the discovery and development of therapeutics, particularly in the field of diabetes, gastrointestinal, and metabolic diseases. The company aims to improve the quality of life for patients with chronic conditions. Zealand Pharma's business model is based on the discovery, development, and commercialization of novel peptide-based therapeutics, utilizing their own technology platform and partnering with pharmaceutical industry collaborators. Their portfolio includes innovative product candidates such as the diabetes treatment Adlyxin and Lixisenatide, both GLP-1 agonists developed in collaboration with Sanofi. They also have products for the treatment of gastrointestinal and heart diseases. Zealand Pharma has a wide pipeline of product candidates at various stages of development, including for the treatment of obesity, fatty liver diseases, and other metabolic conditions. The company works closely with partners such as Sanofi, Boehringer Ingelheim, and Roche. Zealand Pharma is listed on NASDAQ OMX Copenhagen and employs over 200 people in Denmark and the USA. Overall, Zealand Pharma is an innovative biopharmaceutical company with a diverse portfolio of product candidates, focused on collaboration to accelerate product development and improve the quality of life for patients with chronic conditions.
Annual results
Reported figures, DKK · revenue up 14761.3% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 9.2B | 6.5B | 70.1% | — |
| 2024 | 62.0M | -1.1B | -1738.7% | — |
| 2023 | 342M | -703M | -205.6% | — |
| 2022 | 103M | -965M | -936.9% | — |
| 2021 | 292M | -1.0B | -348.6% | — |
ZEAL.CO in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Zealand Pharma A/S are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.